LYSOGENE Logo

LYSOGENE | LYS - Profile, Filings, Stock Info & Investor Relations Data

LYSOGENE | LYS
Filings & Investor Relations Data
Login to Watchlist

Create a free account or log in.

Country
France
Founded
2009
LYSOGENE (LYS)

About LYSOGENE

Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease.

Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders.

Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.

Employees

22

Market Presence

Worldwide

Headquarters

18 RUE JACQUES DULUD
92200, NEUILLY-SUR-SEINE
France

Company Video

Video thumbnail
Click to load video from YouTube

LYSOGENE (LYS)
Key Financial Data

AI-Powered Financial Insights Coming Soon

We are currently processing the filings for this company to provide automated financial statement analysis, key ratios, and risk summaries. Please check back later!

Unlock Full Company Insights & AI Chat

Create a free account or log in to add companies to your watchlist, access more data, and chat directly with filings using our AI assistant (as shown!).

LYSOGENE (LYS)
Filings & Annual Reports
Chat with AI, summarize, and extract data from processed filings! Look for the 'View & AI' button.

Quick Filters:

Advanced Filters

View all types
Filing Information Actions

Insider Trading Activity

No Insider Trades

There is currently no insider trading data available for this company.

LYSOGENE (LYS)
Stock & Investor Information

ISINs

FR0013233475

LEI

969500T64RILK1RD0852

Stock Exchange Listings

Euronext Paris

Primary Stock Exchange Listing

View LYSOGENE on main exchange

Industry Classification